2020
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
Gorman I, Belser A, Jerome L, Hennigan C, Shechet B, Hamilton S, Yazar‐Klosinski B, Emerson A, Feduccia A. Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder. Journal Of Traumatic Stress 2020, 33: 161-170. PMID: 32073177, PMCID: PMC7216948, DOI: 10.1002/jts.22479.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPrimary endpointPlacebo/active controlPhase 2 clinical studyStress disorderClinical symptom reductionPrevious inadequate responseClinician-Administered PTSD ScaleLarge magnitude effect sizesSymptom severity scoresPTSD symptom severity scoresMDMA-Assisted PsychotherapyPosttraumatic Growth InventoryDose groupPTSD symptom severityClinical symptomatologySeverity scoreInadequate responseClinical studiesCrossover designSymptom reductionPTSD ScaleControl groupPosttraumatic growthCAPS-IV
2016
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal Of Psychopharmacology 2016, 30: 1165-1180. PMID: 27909164, PMCID: PMC5367551, DOI: 10.1177/0269881116675512.Peer-Reviewed Original ResearchConceptsAnti-depressant effectsCancer-related anxietyQuality of lifeCancer-related psychological distressLife-threatening cancerPrimary outcomeCrossover trialTherapeutic effectPsilocybin treatmentSustained benefitMedical outcomesSymptom reductionSignificant anxietyExistential distressPatientsPsychological distressDepressionSpiritual wellbeingCancerAnxietyPsilocybinTrialsOutcomesTreatmentDistress